Cite
MLA Citation
E. Lawitz et al.. “A phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus.” Journal of viral hepatitis, vol. 22, no. 12, 2015, pp. 1011–1019. http://access.bl.uk/ark:/81055/vdc_100026687474.0x00001a